New drugs: ranibizumab, posaconazole, and darunavir.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA, USA.
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents / Q000627:therapeutic use; D000069454:Darunavir; D017277:Drug Approval; D004345:Drug Industry / Q000639:trends; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D008268:Macular Degeneration / Q000145:classification / Q000188:drug therapy; D000069579:Ranibizumab; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D014230:Triazoles; D042461:Vascular Endothelial Growth Factor A; C101425:posaconazole; D000069454:Darunavir; D000069579:Ranibizumab